CEO, President, CFO and Head of Aastrom Biosciences Inc. (ASTM) Timothy M Mayleben bought 17,600 shares on 05/21/2010 at an average price of $ 1.42.
Aastrom Biosciences, Inc. is developing autologous cell products for multiple repair or regeneration of human tissues, based on its technology for tissue repair of the cell. Aastrom Biosciences Inc. has a market capitalization of $ 41,800,000, saw their shares trade around $ 1.48 and the P / S 229.7.
Aastrom Biosciences, Inc. financial results for the second quarter ended 31 December 2009, and announced the progress of the last stage of clinical development programs and business operations. Total revenue for the quarter and six months to 31 December 2009, including product sales totaled $ 16,000 and $ 89,000, compared to $ 28,000 and $ 55,000 for the same period in fiscal 2009.
Subscribe To
Posts
Comments
